Ripple Therapeutics is the therapeutics/drug delivery spin out of Interface Biologics, Inc. (IBI) after the sale of its surface modification business to Evonik (ETR:EFK) was completed.
Ripple’s Epidel technology is a sustained release non-polymeric prodrug delivery platform that provides for zero order release kinetics via surface erosion. The prodrug chemistry is applicable across a range of drug classes and form factors (injectable cylinders, microspheres, device coatings) and the drug release kinetics can be engineered via a combination of chemistry and physical properties (surface area). Our lead product (IBE-814 IVT) is a fully degradable intravitreal dexamethasone prodrug implant targeting Diabetic Macular Edema, Retinal Vein Occlusion and Non-infectious Uveitis indications. Our target product profile is zero-order drug release for 6-9 months with a 30G needle and 1/10th the loading of the leading commercial IVT product which suggests a potential to reduce steroid related cataract and IOP AEs. We have a strong pre-clinical data set (presented by Dr. Barry Kuppermann at ARVO) and the FDA has confirmed an abbreviated regulatory path via 505(b)(2). We are currently planning a 50 patient, two dose Phase II clinical trial which will be initiated in Australia in Q3 2020.
We are in the process of raising a ~$25M Series A round which will allow us to complete the Phase II clinical trial for our lead program as well as to continue to develop our technology platform.
As a key member of the management team, the Vice President of Strategic Planning & Business Development has shared responsibility for the company’s strategic direction. (S)he will bring the voice of the patient to the team, lead the commercialization efforts and play a key role in raising the ~$25M Series A round. Ongoing, (s)he will work closely with IBI’s Leadership Team to identify, scope and prioritize new opportunities, helping to focus development efforts on the most viable commercial applications based on market opportunity, technical approach and most expeditious clinical/regulatory pathway. (S)he will also take the lead on identifying potential commercial partners for each application and be responsible for initiating dialogue, convincing partners of the technical/commercial opportunity and signing commercial agreements (development funding, joint venture, product acquisition, etc.)
Flexible depending upon candidate. Since Ripple Therapeutics is located in Toronto, Canada, it is anticipated that the successful candidate, if not local, will be spend approximately two working weeks per month in Toronto.
To apply for this position, please send a resume in confidence to: email@example.com
We thank all applicants for their interest. Only those selected for an interview will be contacted.